Search for: "Mylan Pharmaceuticals"
Results 521 - 540
of 739
Sort by Relevance
|
Sort by Date
10 Nov 2010, 1:11 am
Roche (Filewrapper) (Property, intangible) US: Senator Sanders letter to FDA: U.S. needs an ethical pathway for biological products (KEI) (FDA Law Blog) US: Daiichi Sankyo seeks review and correction of patent term adjustment calculation for patent relating to ‘nucleoside and oligonucleotide analogues’ (Patent Docs) US: CAFC in Abraxis v Navinta: remembering Stanford/Roche (IPBiz) Products Alimta (Pemetrexed) – US: Eli Lilly files patent infringement complaint against Teva in… [read post]
3 Nov 2010, 1:21 am
No – discussion of patent-eligibility standards for genes (Patent Baristas) US: Appellees file reply brief in Therasense v Becton Dickinson (Patent Docs) US: Another Capitol Hill missive objects to the inclusion of patent settlement provisions in FY 2011 Appropriations Bill (FDA Law Blog) US: REMS and 180-day exclusivity forfeiture – some interesting disclosures to the SEC (FDA Law Blog) Products Botox (Botulinum) – EU: General Court upholds opposition to BOTUMAX Community… [read post]
27 Oct 2010, 3:38 am
Abbott (EPLAW) Lunesta (Eszopiclone) – US: Cobalt Pharmaceuticals and Sepracor settle Lunesta patent litigation (Patent Docs) Mirapex (Pramipexole) – US: Mylan receives approval for generic version of Mirapex tablets (SmartBrief) Oracea (Doxycyline) – US: Mylan seeks declaratory judgment of non-infringement and invalidity based on ANDA filing: Mylan v Galderma (Patent Docs) Perlane, Restylane (Hyaluronic acid) – US: Genzyme files patent… [read post]
20 Oct 2010, 1:20 pm
Mylan, Inc., 2010 WL 2008797, slip op. [read post]
19 Oct 2010, 10:42 pm
General WTO paragraph 6 meeting aims at improved use of health waiver (IP Watch) The absence of investment in new antibiotics (IPBiz) Integration of intellectual property and regulatory exclusivity strategies for life science companies (IP Spotlight) Pharmaceutical companies can innovate if they want to (profitability through simplicity) Medicines Patent Pool seeks business director (IP Watch) WHO moves IP, innovation out of Director General’s office (IP Watch) A rights-poor… [read post]
12 Oct 2010, 8:56 pm
Highlights this week included: Aricept(Donepezil) –US: Declaratory judgment jurisdiction for subsequent Paragraph IV filers: Teva Pharmaceuticals USA, Inc. v. [read post]
6 Oct 2010, 4:22 am
(profitability through simplicity) US: Yeda Appeals Board decision favoring Abbott in TBP-II interference (Holman’s Biotech IP Blog) US: Jury finds Scruggs wilfully infringed Monsanto patents, awards at least $9 million in damages (Holman’s Biotech IP Blog) US: Marcy Kaptur’s bill to create a compulsory license for patented seeds: the Seed Availability and Competition Act of 2009 (KEI) US: Glaxosmithkline Biologicals seeks review of BPAI decision concerning isolated protein from B… [read post]
28 Sep 2010, 3:14 pm
Teva Pharmaceuticals USA Inc. et al. [read post]
24 Sep 2010, 1:15 pm
Mylan Labs, Inc., 520 F.3d 1358 (Fed. [read post]
15 Sep 2010, 2:40 am
(Afro-IP) Africa: Giving consumers power in the battle against counterfeits (Afro-IP) Australia: Review Four Corners’ ‘Body Corporate’ program on gene patenting (Patentology) India: Roche and Novartis, finally, manage to defend their patents in oppositions filed by Cipla (Spicy IP) South Africa: San people push for new legislation – demand protection for indigenous knowledge and IP including medicinal remedies derived from plants including Hoodia (Afro-IP) US: PHOSITA:… [read post]
13 Sep 2010, 9:59 pm
., Mylan Inc., Mylan Laboratories, Inc., and Mylan Pharmaceuticals, Inc. [read post]
9 Sep 2010, 7:09 pm
Zenith Goldline Pharmaceuticals, Inc., 471 F.3d 1369, 1377-79 (Fed. [read post]
7 Sep 2010, 6:10 pm
biuras, Amgen Europe BV (The SPC Blog) Aricept (Donepezil) – US: District Court denies Apotex declaratory judgment motion on generic Aricept; does not accept ‘prompt launch’ and ‘indefinite delay’ jurisdiction theories (FDA Law Blog) Chantix (Varenicline) – US: Pfizer files patent infringement complaint against Mylan following Para IV challenge (Patent Docs) (AboutLawsuits.com) Copaxone (Glatiramer) – US: Court denies Sandoz/Momenta’s summary… [read post]
5 Sep 2010, 9:24 pm
• Defendants: Mylan Inc.; Mylan Pharmaceuticals Inc. [read post]
2 Sep 2010, 10:51 am
Mylan Labs, Inc., 520 F.3d 1358 (Fed. [read post]
31 Aug 2010, 10:01 pm
(Spicy IP) India: DIPP discussion paper on compulsory licensing in the Indian Pharmaceutical sector: An ‘acquired’ afterthought? [read post]
25 Aug 2010, 12:37 am
Torrent Pharmaceuticals Ltd. et al. [read post]
19 Aug 2010, 9:55 pm
By James DeGiulio -- Lilly's Patent for Strattera Found Invalid, Lilly Appeals to Federal Circuit Teva Pharmaceuticals USA, Mylan Pharmaceuticals, and Apotex successfully argued that Eli Lilly's patent for the ADHD drug Strattera (U.S. [read post]
18 Aug 2010, 12:19 am
Caraco Pharmaceutical Labs and Sun Pharmaceutical Ind. [read post]
12 Aug 2010, 9:18 pm
By James DeGiulio -- Cephalon and Mylan Pharmaceuticals Agree to Drop Two Patents from Nuvigil Patent Suit Cephalon Inc. and Mylan Pharmaceuticals Inc. have agreed to drop two of the three patents originally involved in their infringement suit over the narcolepsy drug Nuvigil. [read post]
